Dolthera GmbH focuses on developing innovative drugs that use oligonucleotides to target chronic inflammatory respiratory system and skin diseases, as well as transplant rejection, cardiovascular disease, and autoimmune disease. With a strong emphasis on areas with high unmet medical need and commercial potential, Dolthera aims to become a leading company in the research and commercial development of this drug class.